Stability of extemporaneously prepared cinacalcet oral suspensions
- 1 May 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 75 (9) , e236-e240
Abstract
Purpose The stability of extemporaneously prepared cinacalcet suspensions over 90 days was evaluated. Methods Cinacalcet 5-mg/mL suspension was prepared by triturating 30-mg cinacalcet tablets. Twelve 30-mL batches were prepared with a 1:1 mixture of Ora-Plus and either Ora-Sweet or Ora-Sweet SF (sugar free). Three suspensions of each kind were stored at both room temperature and refrigerated conditions. A 1-mL sample was taken from each bottle at 0, 7, 18, 32, 64, and 90 days. Each sample was assayed using high-performance liquid chromatography (HPLC). A new HPLC method for evaluating drug peaks of pure cinacalcet was developed. Stability was defined as retention of at least 90% of the initial drug concentration. Results The HPLC method established in this study serves as a novel assay for evaluating cinacalcet oral suspensions. For all suspensions tested at individual conditions, the concentration remained above 90% of the initial concentration for 90 days of storage with the exception of Ora-Plus and Ora-Sweet SF suspensions stored under refrigeration, which were stable for 64 days. Usual sedimentation of the suspensions occurred over time but resolved with agitation; there was no other change in visual appearance of the suspensions over the course of the 90-day study. The color and odor of the suspensions throughout the study remained unchanged with respect to the initial time point. Conclusion Extemporaneously compounded cinacalcet 5-mg/mL oral suspensions prepared with a 1:1 mixture of Ora-Plus and either Ora-Sweet or Ora-Sweet SF and stored in 2-oz amber polypropylene plastic bottles were stable for at least 64 days at room temperature and under refrigeration.Keywords
This publication has 4 references indexed in Scilit:
- Cinacalcet in Pediatric and Adolescent Chronic Kidney DiseaseMedicine, 2015
- Development and Validation of a Stability-indicating RP-UPLC Method for the Estimation of Impurities in Cinacalcet Hydrochloride API and its FormulationScientia Pharmaceutica, 2015
- Liquid chromatographic separation, determination and ESI-MS/MS, FT-IR and NMR characterization of the forced degradation products of cinacalcetAnalytical Methods, 2014
- Cinacalcet for secondary hyperparathyroidism in children with end-stage renal diseasePediatric Nephrology, 2008